Trendlines Group Ltd. · SGX:42T
Trendlines — The Trendlines Group — Investor Presentation (March 2023)
25 slides from Trendlines's investor presentation, March 2023
Slide 1: Investing to improve the human condition: Food and Health
Investing to improve the human condition Food and Health Steve Rhodes Todd Dollinger Haim Brosh Chair and CEO Chair and CEO CFO March 2023
Slide 2: Legal disclaimer
Legal disclaimer Important notice This presentation is for informational purposes only and does not constitute or form any part of any offer for sale or subscription of, or solicitation of, any offer to buy or subscribe for any securities of The Trendlines Group Ltd. (“Company”) or any of its portfo
Slide 3: Who we are
Who we are Trendlines is an Israel-based company that trades in Singapore on the SGX (42T) and in the USA on the OTCQX (TRNLY). 3
Slide 4: We invest in agrifood and medical tech innovation to improve the human condition
We invest in agrifood and medical tech innovation to improve the human condition 15 years’ investment 56* portfolio 20 advanced-stage 10 exits and company companies companies building experience * including consolidated portfolio companies 9.7X return and 175% IRR on exits Equity US$96 million (31.1
Slide 5: Leadership
Leadership Todd Dollinger Steve Rhodes Haim Brosh Chair and CEO Chair and CEO CFO Trendlines’ Founder; Trendlines’ Founder; 20 years’ over 40 years’ over 40 years’ managerial experience experience, deep and financial developing innovative understanding of experience in products from investing and bu
Slide 6: Board of Directors
Board of Directors Todd Dollinger Steve Rhodes Elka Nir Zeev Bronfeld Chair and CEO Chair and CEO Lead Independent Non-Executive Director Director Trendlines’ Founder; Trendlines’ Founder; Significant experience over 40 years’ over 40 years’ 30 years’ experience in the management experience experien
Slide 7: Strategic partnerships for growth
Strategic partnerships for growth Chairman Vincent Tchenguiz • Librae Holdings is Trendlines’ • Investor in Trendlines’ IPO, • Co-founded venture fund with largest shareholder (27.3%) holding 2.9% Trendlines for innovative agrifood investing • Trendfood has invested $10M in • Investor and acquirer o
Slide 8: A taste of our portfolio
A taste of our portfolio. “s: trendlines
Slide 9: Some portfolio stats
Some portfolio stats 56* 17 20 8 portfolio revenue-stage companies with consolidated companies companies strategic companies partnerships 23 33 agrifood medtech * including consolidated portfolio companies 9
Slide 10: The natural food color revolution
The natural food color revolution A broad-spectrum of healthy plant-based colors produced via Founded 2018; fermentation technology, using baker’s yeast as a biofactory. 23 employees; Phytolon’s high-quality and cost-effective pigments offer value Yokne’am Illit, IL for consumers, the environment an
Slide 11: 4 more agrifood frontrunners
4 more agrifood frontrunners 23 agrifood portfolio companies Early-stage prediction of Technology platform for Artificial intelligence Orally-administered disease crop yields in orchards harvesting greenhouse analytics employing drones prevention for shrimp and and vines tomatoes for user-generated
Slide 12: Nonsurgical prolapse repair device
Nonsurgical prolapse repair device Minimally invasive, nonsurgical, incision-free and mesh-free repair device to treat pelvic organ prolapse (POP) in the ambulatory or office-based settings. Founded 2014 Achievements CEO Edit Goldberg • Received FDA clearance (April 2022) IP Granted US patent, • Suc
Slide 13: 4 more leading medtech companies
4 more leading medtech companies 33 medtech portfolio companies Meniscus repair system Removable stent following Digital home dialysis A small, game-changing • FDA and CE clearance sinus surgery device to prevent preterm birth. • FDA clearance • Launched initial • FDA clearance • FIH clinical study
Slide 14: Let's look at the numbers
Let’s look at the numbers. “s: trendlines
Slide 15: Portfolio value with cumulative exit proceeds
Portfolio value with cumulative exit proceeds US$ 160 millions 140 Portfolio value (w/o 8 consolidated companies) 120 Cumulative exit proceeds 100 80 60 40 20 0 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 15
Slide 16: Portfolio cluster values
Portfolio cluster values Non-IFRS Value Fair Value of Trendlines’ Share Cluster of Trendlines’ (additional information) To better evaluate our portfolio, we divided Share (US$'000) (US$'000) it into 12 “clusters”, based on their activities. Aquaculture & Animal Health US$5,038 US$8,376 Here is the t
Slide 17: Medtech portfolio clusters
Medtech portfolio clusters Home Urology & Spine & Cardiology, Neurology Healthcare Women’s Health Orthopedics & Anesthesia IFRS Value: US$6,138 IFRS Value: US$11,142 IFRS Value: US$10,462 IFRS Value: US$4,301 Non-IFRS: US$13,074 Non-IFRS: US$27,506 Non-IFRS: US$14,261 Non-IFRS: US$6,495 AyzerSense |
Slide 18: Agrifood portfolio clusters
Agrifood portfolio clusters Crop Digitization Future Food Protection & Robotics & Ingredients IFRS Value: US$6,439 IFRS Value: US$7,979 IFRS Value: US$10,926 Non-IFRS: US$9,633 Non-IFRS: US$16,294 Non-IFRS: US$18,729 EcoPhage | AgroScout | FruitSpec | AlgaHealth | Celleste | IBI-Ag | ProJini MetoMot
Slide 19: Book value vs. exit value
Book value vs. exit value US$ millions 60 50 40 30 4.4X is the increase in value 20 of our ten exits, compared to 10 their pre-exit book value. 0 Trendlines’ pre-exit book value Trendlines’ book value at exit 19
Slide 20: Investments raised by portfolio companies
Investments raised by portfolio companies* 45 100,000 US$ millions 40 90,000 80,000 35 70,000 30 60,000 25 50,000 20 40,000 15 30,000 10 20,000 5 10,000 0 0 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 Total # of companies that raised Total amount raised *Including vent
Slide 21: FY 2022: Key Financial Metrics
FY 2022: Key Financial Metrics 31 December 2022 31 December 2021 Portfolio value: US$89.8 million US$83.0 million Total Equity: US$95.9 million US$102.5 million NAV per share: US$0.11 US$0.13 Net (loss)/profit US$ (15.2 million) US$6.0 million 21
Slide 22: Leveraging 2022 achievements
Leveraging 2022 achievements 22
Slide 23: Selected 2022 achievements
Selected 2022 achievements Selected raises Strategic collaborations Regulatory Clinical & field trials Completed to US$19 million FDA clearance US$14.5million US$1.6 million FDA breakthrough device designation US$2.8 million 23
Slide 24: Investing to improve the human condition
Investing to improve the human condition SGX: 42T Steve Rhodes, Chair and CEO OTCQX: TRNLY steve@trendlines.com +972.72.260.7000 Todd Dollinger, Chair and CEO www.trendlines.com todd@trendlines.com Haim Brosh, CFO March 2023 haim@trendlines.com
Slide 25: Notes and Disclaimer
Notes and Disclaimer The additional information (Non-IFRS value) which, as stated, differs from the IFRS fair value at which we carry these investments on our balance sheet, were calculated on the basis of recent portfolio company transactions (last 12 months), as follows: 1. In cases where the last
The Trendlines Group — Investor Presentation (March 2023) on 6ix